The Fly

CymaBay price target raised to $13 from $10 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on CymaBay to $13 from $10 and keeps an Overweight rating on the shares. Cantor Fitzgerald maintained CymaBay as a top pick, and believes there is more value to be unlocked heading into the Phase 3 primary biliary cholangitis data from seladelpar, expected in 3Q23, the analyst tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CBAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed